Inactive Instrument

AIT Therapeutics Inc Stock price OTC Bulletin Board

Equities

Medical Equipment, Supplies & Distribution

Sales 2024 * 1.43M Sales 2025 * 13.3M Capitalization 79.86M
Net income 2024 * -62M Net income 2025 * -64M EV / Sales 2024 * 47.3 x
Net cash position 2024 * 12.15M Net Debt 2025 * 2.95M EV / Sales 2025 * 6.23 x
P/E ratio 2024 *
-0.89 x
P/E ratio 2025 *
-0.96 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.06%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 53 17-01-12
Director of Finance/CFO 53 21-08-31
President 50 17-01-12
Members of the board TitleAgeSince
Director/Board Member 58 15-07-31
Director/Board Member 62 18-08-12
Director/Board Member 57 17-08-09
More insiders
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Company’s areas of focus with LungFit are persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology that generates on-demand NO from ambient air and, regardless of dose or flow, delivers it to a ventilator circuit. The LungFit can generate up to 400 parts per million (ppm) of NO.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Beyond Air, Inc.
  4. Stock AIT Therapeutics Inc - OTC Bulletin Board